December 13, 2021 -- Smart Immune is collaborating with Memorial Sloan Kettering Cancer Center (MSK) with the goal of expanding its ProTcell pipeline to address the exhaustion of T-cell therapy and fulfill unmet medical needs in the treatment of liquid and solid cancers.
Smart Immune's T-cell progenitors (ProTcell) improves on conventional approaches to CAR T-cell therapies, which rely on mature T cells to generate a naïve, long-lasting, exhaustion-free CAR T cell population. MSK will contribute to the development of the CAR-ProTcell platform in a mouse-to-mouse model, and Smart Immune will lead the human model.
ProTcell progenitors can be efficiently transduced with a lentiviral vector, according to the groups. The collaboration will further optimize transduction and culturing conditions to perform in vitro and in vivo preclinical studies on ProTcell transduced with a CD19 CAR lentiviral vector.
No financial agreements were disclosed.